Literature DB >> 27146827

Sharing of Investigational Drug Among Participants in the Voice Trial.

Jeeva Moodley1, Sarita Naidoo2, Jayajothi Moodley2, Gita Ramjee2,3,4.   

Abstract

Product sharing among participants can impact on adherence and compromise the outcome in clinical trials. We describe incidents of product sharing at the Durban clinical research sites conducting the VOICE trial. The Durban sites enrolled 2750 women with 1103 and 1647 participants randomized to the vaginal gel and oral tablet arms respectively. Monthly pill and applicator counts including product assessments were conducted by pharmacists. Discrepancies with product counts prompted discussions with participants. Thirty-two cases of product sharing were identified. Vaginal gels were more commonly shared than oral tablets. Product sharing between study participants and their female friends or relatives living in the same household was identified as the most common source of product sharing in this analysis. Study product counts and pharmacist-driven discussions with participants may help to identify reasons for product sharing and inform the development of strategies for PrEP implementation outside of the research setting. ClinicalTrials.gov number: NCT00705679.

Entities:  

Keywords:  HIV prevention; Pill count; Pre-exposure prophylaxis; Product sharing; VOICE

Mesh:

Substances:

Year:  2016        PMID: 27146827      PMCID: PMC5071120          DOI: 10.1007/s10461-016-1414-x

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  29 in total

Review 1.  The clinician as investigator: participating in clinical trials in the practice setting.

Authors:  Ellis W Lader; Christopher P Cannon; E Magnus Ohman; L Kristin Newby; Daniel P Sulmasy; Robyn J Barst; Joan M Fair; Marcus Flather; Jane E Freedman; Robert L Frye; Mary M Hand; Robert L Jesse; Frans Van de Werf; Fernando Costa
Journal:  Circulation       Date:  2004-06-01       Impact factor: 29.690

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Eliminating bias in randomized controlled trials: importance of allocation concealment and masking.

Authors:  Anthony J Viera; Shrikant I Bangdiwala
Journal:  Fam Med       Date:  2007-02       Impact factor: 1.756

Review 4.  Design of randomized controlled trials.

Authors:  Kenneth Stanley
Journal:  Circulation       Date:  2007-03-06       Impact factor: 29.690

Review 5.  Long-acting rilpivirine for HIV prevention.

Authors:  Akil Jackson; Ian McGowan
Journal:  Curr Opin HIV AIDS       Date:  2015-07       Impact factor: 4.283

Review 6.  Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies.

Authors:  Linda J Koenig; Cynthia Lyles; Dawn K Smith
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

7.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

8.  The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.

Authors:  Amy L Corneli; Kevin McKenna; Brian Perry; Khatija Ahmed; Kawango Agot; Fulufhelo Malamatsho; Joseph Skhosana; Jacob Odhiambo; Lut Van Damme
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

9.  Preexposure prophylaxis (PrEP) of HIV infection in France: a nationwide cross-sectional study (PREVIC study).

Authors:  E Rosenthal; L Piroth; E Cua; A Joulié; I Ravaux; M Chauveau; K Lacombe; L Cotte; P Bonnard; L Weiss; M Longuet; C Pradier; P Cacoub
Journal:  AIDS Care       Date:  2013-06-11

10.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.